154 related articles for article (PubMed ID: 19640245)
1. Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective.
Hoyer H; Perera G; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2010 Jan; 36(1):31-44. PubMed ID: 19640245
[TBL] [Abstract][Full Text] [Related]
2. [Drug delivery system for the treatment of osteoporosis].
Satoh T; Yoshida G; Orito Y; Koike T
Nihon Rinsho; 1998 Mar; 56(3):742-7. PubMed ID: 9549367
[TBL] [Abstract][Full Text] [Related]
3. Patient experience with a new teriparatide delivery device.
Dore RK; Feldman RG; Taylor KA; See K; Dalsky GP; Warner MR
Curr Med Res Opin; 2009 Oct; 25(10):2413-22. PubMed ID: 19656016
[TBL] [Abstract][Full Text] [Related]
4. What is new in the treatment of steroid-induced osteoporosis?
Liu RH; Werth VP
Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
Tashjian AH; Gagel RF
J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
[No Abstract] [Full Text] [Related]
6. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.
Stroup JS; Rivers SM; Abu-Baker AM; Kane MP
Pharmacotherapy; 2007 Jun; 27(6):779-88. PubMed ID: 17542760
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
8. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
9. Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model.
Lehman RA; Dmitriev AE; Cardoso MJ; Helgeson MD; Christensen CL; Raymond JW; Eckel TT; Riew KD
Spine (Phila Pa 1976); 2010 Jan; 35(2):146-52. PubMed ID: 20081509
[TBL] [Abstract][Full Text] [Related]
10. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
Sowa H; Hamaya E; Yamamoto T
Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
[TBL] [Abstract][Full Text] [Related]
11. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
Nakamura Y
Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
[TBL] [Abstract][Full Text] [Related]
12. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
Saito M; Marumo K
Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
[TBL] [Abstract][Full Text] [Related]
13. [Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
Yamamoto T; Hamaya E; Sowa H
Clin Calcium; 2012 Mar; 22(3):399-406. PubMed ID: 22370307
[TBL] [Abstract][Full Text] [Related]
14. Anabolic therapy for osteoporosis.
Bilezikian JP
Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
[TBL] [Abstract][Full Text] [Related]
15. [Effect and role of teriparatide in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2012 Mar; 22(3):309-14. PubMed ID: 22370296
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
17. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
18. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
[TBL] [Abstract][Full Text] [Related]
19. Anabolic therapy in glucocorticoid-induced osteoporosis.
Sambrook PN
N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
[No Abstract] [Full Text] [Related]
20. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
Miyauchi A
Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]